Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial

Streptococcus pneumoniae infection is a major global public health concern in older adults, especially as life expectancy continues to increase in most countries, including India. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) with the ability to enhance immunity (immunologic memory) o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Hum Vaccin Immunother
Autors principals: Solanki, Bhagirath B., Juergens, Christine, Chopada, Manojkumar B., Supe, Pravin, Sundaraiyer, Vani, Le Dren-Narayanin, Natacha, Cutler, Mark W., Gruber, William C., Scott, Daniel A., Schmoele-Thoma, Beate
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2017
Matèries:
Research Papers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5612423/
https://ncbi.nlm.nih.gov/pubmed/28881165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2017.1331796
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars